Reproductive Factors Associated to Human Papillomavirus Infection in Iranian Woman
Objective: In recent years, humman papilomaviruses (HPV) infection is the most common type of sexual trasmitted diseases (STD) in majority of countries. It's a significant source of morbidity and mortality worldwide. In this study, we aimed to compare the history of reproductive disease between two groups of Iranian women with and without HPV infection through colposcopy precedure.
Materials and methods: This case -control study included 210 women reffered to a training gynecology hospital of Tehran University of Medical Science in Tehran. Case group was composed of 70 women with diagnosis of HPV infection, while control group was composed of 140 women with no sign of mentioned-infectious diseases of the control group. Reproductive history was prepared using the standard questionnaire, and obtianed data were analized by SPSS 20.
Results: OUR FINDINGS SHOWED THAT THE RISK FACTORS FOR HPV INFECTION WERE AS FOLLOWS: low parity (p = 0.000), reduction of number of weekly sexual intercourse (p = 0.000), no consumption of oral contraceptive pill (OCP) (p = 0.006), and history of withdrawal contraceptive method (p = 0.001).
Conclusion: Improvement of our knowledge about reproductive factors associated with HPV may help us to identify women at risk and to develope different methods of preventive interventions.
2. Bhatla N, Datta P, Dar L, Patro AR., Gulati A, Kriplani A, & et al. Prevalence of human papillomavirus infection among young women in North India. Cancer Epidemiology2010; 34: 157-61.
3. Burchell AN, Tellier PP, Hanley J, Coutle FO, Franco EL. Human Papillomavirus Infections Among Couples in New Sexual Relationships. Epidemiology 2010;21 : 31-7.
4. Castellsague X, de Sanjose S, Aguado T, Louie KS, Bruni L, et al., editors. HPV and Cervical Cancer in the World: 2007 Report. Vaccine. 2007;25(Suppl 3):c1–c230.
5. Diaz M. LHuman Papilloma Virus – Prevention and Treatment. Obstetrics & Gynecology Clinics of North America 2008;35 : 199- 217.
6. Dunne EF, Unger ER, Sternberg M, Mcquillan G, Swan DC, Patel SS, et al. Prevalence of HPV Infection Among Females in the United States. The Journal of the American Medical Association 2007; 297: 813- 9.
7. Franceschi S, Bardin A, Vaccareela S, Clifford GM, Lissowska J, Rekosz M, et al. Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Euroean Journal of Cancer 2008;44 : 557- 64.
8. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
9. Hager WD. Human Papilloma Virus Infection and Prevention in the Adolescent Population. Journal of Pediatric Adolescent Gynecology 2009;22 : 197-204.
10. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus—related disease. Am J Obstet Gynecol 2004; 191: 114-20.
11.Kahn JA, Shikary T, Bernstein DI, Jin Y, Zimet GD, Rosenthal SL. Epidemiology and risk factors for human papillomavirus infection in a diverse sample of lowincome young women. Journal of Clinical Virology2009; 46: 107- 11.
12.Kyriakis KP, Hadjivassiliou M, Paparizos VA, Riga P, Katsambas A. Determinants of genital wart case detection rates among STD clinic attendees in Athens, Greece. Int J Dermatol 2005; 44 : 650-3.
13.Maggino T, Casadei D, Panontin E, Fadda E, Zampieri MC, Dona MA, et al. Impact of an HPV diagnosis on the quality of life in young women. Gynecologic Oncology2007; 107: S175- 79.
14.Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. The Journal of American Medical Association 2001;285: 2995–3002.
15.National Cancer Institute. HPV and cervical cancer. 2012: 1- 5. Available at:http://www.cancer.gov/cancertopics/factsheet/Risk/Fs3_20.pdf.
16. Professional Advisory Board of the Australia and New Zealand HPV Project. Guidelines for the Management of Genital HPV in Australia and New Zealand. 6th ed, 2010: 1- 36. Available at : http://www.hpv.org.nz/pdfs/HPV%20 Guidelines%202010_FA.pdf
17.Safaei A, Khanlari M, Momtahen M, Monbati A, Robati M, Amooei S, & et al. 2010. Prevalence of highrisk human papillomavirus types 16 and 18 in healthy women with cytologically negative pap smear in Iran.Indian Journal of Pathology & Microbiology 53 : 681- 5.
18.Sukvirach S, Smith JS, Tunsakul S, Munoz N, Kesararat V, Opasatian O, et al. Population-Based Human Papillomavirus Prevalence in Lampang and Songkla, Thailand. The Journal of Infectious Diseases2003; 187:1246- 56.
19.Tchernev G. Sexually transmitted papillomavirus infections: epidemiology, pathogenesis,clinic, morphology, important differential diagnostic aspects, current diagnostic and treatment options. Anais Brasileiros de Dermatologia2009; 84: 377- 89.
20.Trottier H, Franco EL. Human Papillomavirus and Cervical Cancer: Burden of Illness and Basis for Prevention. The American Journal of Managed Care 2006; 12: S462- 72.
21.Wheeler CM. Natural History of Human Papillomavirus Infections, Cytologic and Histologic Abnormalities and Cancer. Obstetrics Gynecology Clinics of North America 2008;35: 519- 36.
22.Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Moscicki AB, et al. External genital warts: diagnosis, treatment, and prevention. Clinical Infectious Diseases 2002;35: S210–24.
23.Winer R.L, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital Human Papillomavirus Infection: Incidence and Risk Factors in a Cohort of Female University Students. American Journal of Epidemiology 2003;157: 218- 26.
24.World Health Organization. Human papillomavirus and cervical cancer. 2008.Retrieved March 1. Available at:http://www.who.int/immunization/topics/hpv/en.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.